Trial Profile

A clinical study of Nicotinamide riboside in Ataxia Telangiectasia

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 26 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nicotinamide riboside (Primary)
Indications Ataxia telangiectasia
Focus Adverse reactions
Sponsors Niagen Bioscience

Most Recent Events

13 Mar 2025 According to ChromaDex Corporation media release, ChromaDex Corp has changed its name to Niagen Bioscience.
05 Nov 2024 New trial record
31 Oct 2024 According to ChromaDex Corporation media release, company has initiated discussions with FDA and plans to file an Investigational New Drug (IND) application with the US FDA in anticipation of conducting human clinical trials.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com